PH26424A - Platinum pharmaceutical agents - Google Patents
Platinum pharmaceutical agents Download PDFInfo
- Publication number
- PH26424A PH26424A PH39898A PH39898A PH26424A PH 26424 A PH26424 A PH 26424A PH 39898 A PH39898 A PH 39898A PH 39898 A PH39898 A PH 39898A PH 26424 A PH26424 A PH 26424A
- Authority
- PH
- Philippines
- Prior art keywords
- compound
- platinum
- formula
- alkyl
- mono
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims description 56
- 229910052697 platinum Inorganic materials 0.000 title description 23
- 239000008177 pharmaceutical agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 190
- 239000000203 mixture Substances 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 42
- 150000002016 disaccharides Chemical class 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 150000002772 monosaccharides Chemical class 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 239000000243 solution Substances 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000002552 dosage form Substances 0.000 description 36
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- 229940093499 ethyl acetate Drugs 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- 238000001990 intravenous administration Methods 0.000 description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 21
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 21
- 229930182830 galactose Natural products 0.000 description 21
- 238000007912 intraperitoneal administration Methods 0.000 description 18
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 17
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 16
- 229960002442 glucosamine Drugs 0.000 description 16
- 238000007918 intramuscular administration Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000000644 isotonic solution Substances 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 206010033128 Ovarian cancer Diseases 0.000 description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 13
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 13
- 229910001863 barium hydroxide Inorganic materials 0.000 description 13
- 201000010536 head and neck cancer Diseases 0.000 description 13
- 208000014829 head and neck neoplasm Diseases 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 208000024313 Testicular Neoplasms Diseases 0.000 description 12
- 206010057644 Testis cancer Diseases 0.000 description 12
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000000969 carrier Substances 0.000 description 12
- 208000029742 colonic neoplasm Diseases 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 201000003120 testicular cancer Diseases 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
- 230000008034 disappearance Effects 0.000 description 11
- 150000002540 isothiocyanates Chemical class 0.000 description 11
- 229960004316 cisplatin Drugs 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 10
- 229940035423 ethyl ether Drugs 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- -1 N-acetylamino Chemical group 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 239000000945 filler Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 230000000704 physical effect Effects 0.000 description 8
- 125000003132 pyranosyl group Chemical group 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 7
- 239000006186 oral dosage form Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 150000008266 deoxy sugars Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930182470 glycoside Chemical group 0.000 description 5
- 150000002338 glycosides Chemical group 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 150000005846 sugar alcohols Chemical class 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 4
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 4
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 4
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 4
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 4
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 4
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 4
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052788 barium Inorganic materials 0.000 description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
- 239000007894 caplet Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000004203 carnauba wax Substances 0.000 description 4
- 235000013869 carnauba wax Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 125000003843 furanosyl group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229940060367 inert ingredients Drugs 0.000 description 4
- 239000006204 intramuscular dosage form Substances 0.000 description 4
- 239000006206 intraperitoneal dosage form Substances 0.000 description 4
- 239000006207 intravenous dosage form Substances 0.000 description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 description 3
- CLOSFPUIYFHGPR-UHFFFAOYSA-L 2-acetamidopropanedioate;barium(2+) Chemical compound [Ba+2].CC(=O)NC(C([O-])=O)C([O-])=O CLOSFPUIYFHGPR-UHFFFAOYSA-L 0.000 description 3
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- PNMDNJALVHCMOX-AVBXVCIKSA-N [(2r,3s,4r,5r)-5-acetamido-3,4-diacetyloxy-6-isothiocyanatooxan-2-yl]methyl acetate Chemical compound CC(=O)N[C@H]1C(N=C=S)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O PNMDNJALVHCMOX-AVBXVCIKSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- DFUVZQDRDFOOCF-UHFFFAOYSA-L [Ba+2].[O-]C(=O)C(C([O-])=O)NC=O Chemical compound [Ba+2].[O-]C(=O)C(C([O-])=O)NC=O DFUVZQDRDFOOCF-UHFFFAOYSA-L 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QLTGEMIEWNAURK-DKWTVANSSA-L (2s)-2-aminobutanedioate;barium(2+) Chemical compound [Ba+2].[O-]C(=O)[C@@H](N)CC([O-])=O QLTGEMIEWNAURK-DKWTVANSSA-L 0.000 description 1
- YWNNXTFWQRXKOO-UBRBJVMESA-N 2-[[(3R,4R,5S,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]amino]-2-(carboxymethylamino)-3-sulfanylidenepropanoic acid Chemical compound C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)NC(C(=O)O)(NCC(=O)O)C=S YWNNXTFWQRXKOO-UBRBJVMESA-N 0.000 description 1
- FPYRGBGIXXZJDX-UHFFFAOYSA-N 2-acetamidopropanedioic acid;barium Chemical compound [Ba].CC(=O)NC(C(O)=O)C(O)=O FPYRGBGIXXZJDX-UHFFFAOYSA-N 0.000 description 1
- LVEGZFXIIKKYTA-UHFFFAOYSA-N 2-iminopropanedioic acid Chemical compound OC(=O)C(=N)C(O)=O LVEGZFXIIKKYTA-UHFFFAOYSA-N 0.000 description 1
- WLEHEWWMHHJASO-UHFFFAOYSA-N 4-aminocyclohexane-1,1-dicarboxylic acid Chemical compound NC1CCC(C(O)=O)(C(O)=O)CC1 WLEHEWWMHHJASO-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CWZMTPMBINXCIA-CMSCEZBTSA-N C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)C(C(=O)O)NC(C(=O)O)(C=S)N Chemical compound C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)COC(C)=O)C(C(=O)O)NC(C(=O)O)(C=S)N CWZMTPMBINXCIA-CMSCEZBTSA-N 0.000 description 1
- 101100522123 Caenorhabditis elegans ptc-1 gene Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001553 barium compounds Chemical class 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ZVYNEIVHNNYCSE-UHFFFAOYSA-N piperidine-4,4-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCNCC1 ZVYNEIVHNNYCSE-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29736889A | 1989-01-17 | 1989-01-17 | |
| US07/301,773 US4946954A (en) | 1989-01-17 | 1989-01-26 | Platinum pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26424A true PH26424A (en) | 1992-07-15 |
Family
ID=26970120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH39898A PH26424A (en) | 1989-01-17 | 1990-01-16 | Platinum pharmaceutical agents |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4946954A (de) |
| EP (1) | EP0462980A4 (de) |
| JP (1) | JP2771326B2 (de) |
| AU (2) | AU5039490A (de) |
| CA (1) | CA2045120A1 (de) |
| HU (1) | HUT59690A (de) |
| IL (1) | IL93090A (de) |
| NO (1) | NO180588C (de) |
| NZ (1) | NZ232134A (de) |
| PH (1) | PH26424A (de) |
| RU (1) | RU2074861C1 (de) |
| WO (1) | WO1990008157A1 (de) |
| ZA (1) | ZA90336B (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041581A (en) * | 1985-10-18 | 1991-08-20 | The University Of Texas System Board Of Regents | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5384127A (en) * | 1985-10-18 | 1995-01-24 | Board Of Regents, The University Of Texas System | Stable liposomal formulations of lipophilic platinum compounds |
| AU614901B2 (en) * | 1989-04-04 | 1991-09-12 | Daikin Industries, Ltd. | New fluorocarbon platinum complexes |
| US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
| AU2701395A (en) * | 1994-06-27 | 1996-01-19 | General Hospital Corporation, The | Graft co-polymer adducts of platinum (ii) compounds |
| ATE246696T1 (de) * | 1995-05-09 | 2003-08-15 | Kreatech Biotech Bv | Verfahren zur herstellung von linkern zwischen markierungsgruppen und bio-organischen molekülen auf der basis von platin für die markierung von bio-organischen molekülen zur entdeckung interessanter biologischer substanzen |
| US5843475A (en) * | 1996-12-06 | 1998-12-01 | Board Of Regents, The University Of Texas System | Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes |
| US6235776B1 (en) | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| US6235782B1 (en) | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| EP2266607A3 (de) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunokonjugate für Krebsbehandlung |
| US6692734B2 (en) | 2000-01-04 | 2004-02-17 | Access Pharmaceuticals, Inc. | N,O-amidomalonate platinum complexes |
| AU2006222657B2 (en) * | 2000-01-04 | 2009-01-15 | Access Pharmaceuticals, Inc. | N,O-amidomalonate platinum complexes |
| US7166733B2 (en) * | 2000-01-04 | 2007-01-23 | Access Pharmaceuticals, Inc. | O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes |
| KR20040074857A (ko) * | 2003-02-19 | 2004-08-26 | 학교법인 이화학당 | Ｎ-치환 아미노디카복실산의 백금(ⅱ) 착물 및 그 제조방법 |
| KR100499340B1 (ko) * | 2003-04-29 | 2005-07-04 | 학교법인 이화학당 | 암 조직 선택성과 생분해성을 갖는폴리포스파젠-백금(ⅱ)착물 복합체 항암제 및 그 제조방법 |
| US7208611B2 (en) * | 2005-02-23 | 2007-04-24 | Xenoport, Inc. | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use |
| RU2319491C1 (ru) | 2006-07-12 | 2008-03-20 | Бадулин Николай Александрович | Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (ее варианты) |
| AU2008331439B9 (en) * | 2007-12-07 | 2014-04-10 | Prana Biotechnology Ltd | Compounds for therapy and diagnosis |
| ES2588979T3 (es) | 2010-08-24 | 2016-11-08 | Dana-Farber Cancer Institute, Inc. | Procedimientos para la predicción de una respuesta contra el cáncer |
| EP2721181B1 (de) | 2011-06-17 | 2019-12-18 | Myriad Genetics, Inc. | Verfahren und materialien zur beurteilung eines allel-ungleichgewichts |
| CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
| CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
| WO2013083058A1 (zh) * | 2011-12-07 | 2013-06-13 | 北京市丰硕维康技术开发有限责任公司 | 一类离去基团是含氨基或烷氨基的羟基酸衍生物的铂类化合物及其制备方法和应用 |
| EP2794907B2 (de) | 2011-12-21 | 2022-11-23 | Myriad Genetics, Inc. | Verfahren und materialien zur bewertung des verlusts der heterozygotie |
| CA2864481C (en) | 2012-02-23 | 2020-07-14 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
| EP2859118B1 (de) | 2012-06-07 | 2017-11-22 | Institut Curie | Verfahren zur detektion der deaktivierung des pfades der homologen rekombination (brca1/2) in menschlichen tumoren |
| US10308986B2 (en) | 2013-03-14 | 2019-06-04 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| CN105705152B (zh) * | 2013-06-14 | 2021-07-09 | 阿卡玛拉疗法有限公司 | 基于脂质的铂化合物和纳米粒子 |
| JPWO2014203691A1 (ja) * | 2013-06-18 | 2017-02-23 | 株式会社ヤクルト本社 | 白金錯体を含有する新規医薬 |
| US11149316B2 (en) | 2013-12-09 | 2021-10-19 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| ES2800673T3 (es) | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| US11358978B2 (en) | 2015-05-19 | 2022-06-14 | Akamara Therapeutics, Inc. | Process for preparing supramolecular platinum-based compounds |
| WO2018175601A1 (en) * | 2017-03-22 | 2018-09-27 | The Regents Of The University Of California | Modified platinum compounds and therapeutic uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115418A (en) * | 1976-09-02 | 1978-09-19 | Government Of The United States Of America | 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity |
| US4284579A (en) * | 1979-07-17 | 1981-08-18 | The United States Of America As Represented By The Of The Department Of Health & Human Services | (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt |
| JPS57123198A (en) * | 1981-01-23 | 1982-07-31 | Shionogi & Co Ltd | Novel platinum complex |
| JPS5921697A (ja) * | 1982-06-24 | 1984-02-03 | Yoshinori Kitani | 新規な白金錯体 |
| US4673754A (en) * | 1983-10-14 | 1987-06-16 | Inco Alloys International, Inc. | Platinum and palladium complexes |
| IL73337A (en) * | 1984-10-28 | 1988-09-30 | Yissum Res Dev Co | Antitumor steroid-platinum complexes and method for the preparation thereof |
| US4587331A (en) * | 1984-12-17 | 1986-05-06 | American Cyanamid Company | Platinum complexes of polyhydroxylated alkylamines and 2-polyhydroxylated alkyl-1,2-diaminoethanes |
| US4882447A (en) * | 1987-02-20 | 1989-11-21 | Tanabe Seiyaku Co., Ltd. | Novel organic platinum complex and process for the preparation thereof |
| DE3879709T2 (de) * | 1987-07-17 | 1993-10-07 | Georgetown University Washingt | Platin-arzneimittel. |
-
1989
- 1989-01-26 US US07/301,773 patent/US4946954A/en not_active Expired - Fee Related
-
1990
- 1990-01-16 PH PH39898A patent/PH26424A/en unknown
- 1990-01-17 AU AU50394/90A patent/AU5039490A/en not_active Abandoned
- 1990-01-17 NZ NZ232134A patent/NZ232134A/en unknown
- 1990-01-17 ZA ZA90336A patent/ZA90336B/xx unknown
- 1990-01-17 RU SU905001256A patent/RU2074861C1/ru active
- 1990-01-17 HU HU901456A patent/HUT59690A/hu unknown
- 1990-01-17 IL IL9309090A patent/IL93090A/en not_active IP Right Cessation
- 1990-01-17 JP JP2503681A patent/JP2771326B2/ja not_active Expired - Lifetime
- 1990-01-17 CA CA002045120A patent/CA2045120A1/en not_active Abandoned
- 1990-01-17 WO PCT/US1990/000171 patent/WO1990008157A1/en not_active Application Discontinuation
- 1990-01-17 EP EP19900902930 patent/EP0462980A4/en not_active Withdrawn
-
1991
- 1991-07-11 NO NO912732A patent/NO180588C/no unknown
-
1994
- 1994-01-31 AU AU54792/94A patent/AU674185B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU5479294A (en) | 1994-03-31 |
| JPH04502767A (ja) | 1992-05-21 |
| NZ232134A (en) | 1992-09-25 |
| EP0462980A4 (en) | 1992-03-11 |
| NO180588B (no) | 1997-02-03 |
| JP2771326B2 (ja) | 1998-07-02 |
| NO912732L (no) | 1991-07-11 |
| HUT59690A (en) | 1992-06-29 |
| RU2074861C1 (ru) | 1997-03-10 |
| NO912732D0 (no) | 1991-07-11 |
| ZA90336B (en) | 1990-10-31 |
| AU674185B2 (en) | 1996-12-12 |
| US4946954A (en) | 1990-08-07 |
| WO1990008157A1 (en) | 1990-07-26 |
| AU5039490A (en) | 1990-08-13 |
| IL93090A0 (en) | 1990-11-05 |
| CA2045120A1 (en) | 1990-07-18 |
| EP0462980A1 (de) | 1992-01-02 |
| IL93090A (en) | 1995-10-31 |
| NO180588C (no) | 1997-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH26424A (en) | Platinum pharmaceutical agents | |
| US4938949A (en) | Treatment of damaged bone marrow and dosage units therefor | |
| US5434256A (en) | Diamine platinum complexes as antitumor agents | |
| US4895936A (en) | Platinum pharmaceuticals | |
| EP0394262B1 (de) | Platin-verbindungen, geeignet zur verwendung als arzneimittel | |
| EP1968991B9 (de) | Bisplatinkomplexe mit antitumorwirkung | |
| EP0376959B1 (de) | Platin-arzneimittel | |
| US4895935A (en) | Platinum pharmaceuticals | |
| HU203246B (en) | Process for producing antitumoural platinum(iv)-diamine complex and pharmaceutical compositions comprising such compound as active ingredient | |
| EP0214862B1 (de) | Antitumor-Platinkomplexe, deren Herstellung und Verwendung | |
| US5041579A (en) | Platinum complexes and uses therewith | |
| PT100272B (pt) | Novo complexo de platina(ii) e processo para a sua preparacao | |
| EP0518645B1 (de) | Platin(II)-Komplex und Antitumormittel | |
| JPS61249993A (ja) | 新規有機白金錯体及びその製法 | |
| CA1265811A (en) | O-alkyl platinum diamine compounds | |
| JPH07233076A (ja) | 制癌剤補助剤 |